ArticleCancer medicine2023

Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+ breast cancer.

Alexis LeVee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.